PFAS Mechanisms in Prostate Carcinogenesis
The prostate is an androgen-dependent organ whose growth and function are driven by testosterone and dihydrotestosterone (DHT) acting through androgen receptors. PFAS compounds interact with androgen receptors — both agonistically and antagonistically depending on compound and concentration — potentially disrupting the hormonal balance that governs normal prostate cell proliferation.
PFAS also promote chronic prostatic inflammation through NF-κB activation and oxidative stress induction. Chronic inflammation is recognized as a driver of prostate cancer initiation and progression, supporting a role for PFAS in promoting the inflammatory microenvironment associated with prostate carcinogenesis.
Occupational and Community Studies
Occupational health studies of male workers in PFAS manufacturing have found elevated prostate cancer incidence, though results have been less consistent than for testicular or kidney cancer. A study of 3M production workers found that those with highest PFOS exposure had significantly elevated prostate cancer risk compared to lower-exposure coworkers.
Community studies in PFAS-contaminated areas show mixed results, in part because prostate cancer is common (1 in 8 U.S. men) and detecting a modest PFAS contribution requires large sample sizes. Studies in the Veneto, Italy contaminated region found elevated prostate cancer rates in high-exposure communities, adding to the evidence base.
PSA Screening and Environmental Context
Prostate-specific antigen (PSA) screening in men over 50 provides early detection of prostate cancer when treatment options are most effective. In PFAS-contaminated communities, prostate cancer screening programs may consider beginning at earlier ages — 45 rather than 50 — for men with significant PFAS exposure history, analogous to recommendations for individuals with other cancer risk factors.
Urological oncologists should incorporate PFAS exposure history into prostate cancer risk assessment, particularly for younger patients (under 60) presenting with de novo prostate cancer — a profile inconsistent with purely age-related carcinogenesis that suggests an environmental contribution.